Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -6.29%39 Quick Ratio is 11.92 as of Mar. 2026, which is 367% above its 10-year median of 2.55. GuruFocus rates STU:FLB with a GF Score™ of 39/100 and a GF Value™ of €0.46 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Standard BioTools ranks better than 96.49% on this metric.
Standard BioTools has a quick ratio of 11.92. It generally indicates good short-term financial strength.
The historical rank and industry rank for Standard BioTools's Quick Ratio or its related term are showing as below:
STU:FLB'
s Quick Ratio Range Over the Past 10 Years
Min: 1.01 Med: 2.55 Max: 11.92
Current: 11.92
During the past 13 years, Standard BioTools's highest Quick Ratio was 11.92. The lowest was 1.01. And the median was 2.55.
STU:FLB's Quick Ratio is ranked better than 96.49% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.89
vs STU:FLB: 11.92
Standard BioTools (STU:FLB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Standard BioTools Quick Ratio Related Terms
Standard BioTools Quick Ratio Historical Data
* Premium members only.
The historical data trend for Standard BioTools's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs SENS, TMCI, SGHT: Quick Ratio Comparison
For the Medical Devices subindustry, Standard BioTools's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Standard BioTools's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Standard BioTools's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (STU:FLB) has a Quick Ratio of 11.92 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Standard BioTools and its competitors. This is 367% above median its historical median of 2.55. Over the past decade, Standard BioTools' Quick Ratio has ranged from 1.01 to 11.92. According to the industry distribution chart, Standard BioTools ranks #30 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 3.5%.
Is Standard BioTools' Quick Ratio too high?
Standard BioTools' current Quick Ratio of 11.92 is 367% above median its 10-year median of 2.55. Over the past 10 years, this metric has ranged from a low of 1.01 to a high of 11.92. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Standard BioTools' value of 11.92 is 530.7% above this industry median. Based on the distribution chart, Standard BioTools ranks #30 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Quick Ratio compare to SENS and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #30 out of 855 companies for Quick Ratio. This places Standard BioTools in the top 4% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.89. Standard BioTools' value of 11.92 is 530.7% above this benchmark. Historically, Standard BioTools' own Quick Ratio has ranged from 1.01 to 11.92 over the past decade. While the company's 10-year median is 2.55 vs. the industry median of 1.89, Standard BioTools has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current Quick Ratio of 11.92 is 530.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current Quick Ratio is 11.92, which is 367% above median its own 10-year median of 2.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.46, compared to a current price of €0.75 — trading 62% above its estimated fair value. The current Quick Ratio is 11.92, which is 367% above median its 10-year median of 2.55 and 530.7% above the Medical Devices & Instruments industry median of 1.89. Standard BioTools' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Quick Ratio is 11.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.75 is trading 62% above its estimated GF Value™ of €0.46.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for STU:FLB:
Quick Ratio: 11.92 (367% above median its 10-year median of 2.55)
GF Value™: €0.46 vs. price of €0.75 (62% above fair value)
Industry Position: 530.7% above the Medical Devices & Instruments median (#30 of 855)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
39GF Score
Get the complete analysis for STU:FLB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
